Developer docs
API playgroundTry for free, no card

Search company profiles

Precisionlife

Full company profile

uuid0002fv7

Namestring
Precisionlife
Legal namestring
PrecisionLife Ltd
Company typeenum
Private
Founded yearint
2015
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWitney, United Kingdom
HQ citystring
Witney
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision medicine AI, combinatorial analytics platform, genetic diagnostic testing, biomarker discovery services, clinical trial enrichment
Industry5 codes
PRIMARYHLAAANAA
Genomic Profiling & Sequencing-Based Precision Medicine
SECONDARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAF
Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code3 codes
  • Medical and Diagnostic Laboratories6215
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Precision Medicine AI Software
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Diagnostic Tests (Mechanostics®)
TypeSubscription Recurring
Description

Revenue from development and commercialization of genetic diagnostic tests including GLP-1 response tests, disease risk prediction tests, and patient stratification tools for healthcare providers and payors.

precisionlife.com
2Biopharmaceutical Partnerships
TypeProfessional Services
Description

Revenue from partnerships with pharmaceutical companies for drug discovery, clinical trial enrichment, patient stratification biomarkers, and drug repurposing opportunities. Includes biomarker discovery services and companion diagnostic development.

precisionlife.com
3Payor-Facing Tests
TypeLicensing Royalties
Description

Mechanism-based tests to help payors and healthcare systems determine where therapies are most clinically and economically justified, supporting value-based reimbursement frameworks.

precisionlife.com
4Laboratory Developed Tests (LDTs)
TypeSubscription Recurring
Description

Revenue from laboratory developed tests commercialized through CLIA-certified laboratory partners, including consumer DNA tests and clinical diagnostic tests.

precisionlife.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1Mechanostics®
Description

A new generation of diagnostic and prognostic tools to accurately identify the cause of disease and personalize interventions, based on precision medicine AI technology.

precisionlife.com
Core offering1 text field

PrecisionLife develops a proprietary AI-driven combinatorial analytics platform that identifies the biological mechanisms driving complex chronic diseases and enables high-resolution patient stratification. The company commercializes the Mechanostics® product line of non-invasive genetic tests for disease risk prediction, treatment response prediction, and patient stratification, and provides biomarker discovery, drug target identification, and clinical trial enrichment services to biopharmaceutical companies, healthcare systems, and payors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Identified over 2,500 genetic signatures for GLP-1 efficacy in 100% of 4,600 patients studied
+4 more records
Product overview1 text field

PrecisionLife offers a unified precision medicine platform centered on its Mechanostics® product line and proprietary Combinatorial Analytics Platform. The core offering includes non-invasive genetic tests that identify disease mechanisms and predict treatment response across 60+ chronic diseases. Key products include GLP-1 response prediction tests (LDT and consumer DNA), endometriosis tests (TRANSCEND), ME/CFS genetic tests, and long COVID diagnostic tests. The company provides additional services including Clinical Decision Support, Drug Discovery, and Clinical Trial Enrichment using mechanism-based patient stratification. All products leverage the Combinatorial Analytics Platform to discover biomarkers invisible to traditional GWAS methods.

Product and service10 records
1Mechanostics®
CategoryDiagnostic Tests
Description

First-in-class, non-invasive genetic tests that leverage PrecisionLife's proprietary AI-driven combinatorial analytics to identify the underlying biological mechanisms driving disease in patients. Enables disease risk prediction, mechanism identification, and precision treatment matching across 60+ chronic diseases.

2Combinatorial Analytics Platform
CategoryAI Analytics Platform
Description

Proprietary AI platform that identifies combinations of genetic variants associated with disease risk and treatment response. Generates 10-100x more signal from data than traditional GWAS approaches, discovering disease mechanisms invisible to other analytical methods.

3GLP-1 Response Prediction Tests
CategoryPharmacogenomic Diagnostic Tests
Description

DNA-based tests (both LDT and direct-to-consumer) that predict individual patient response, safety, and tolerability to GLP-1 receptor agonists. Identifies biomarkers for glycemic control (HbA1c) and weight loss (BMI) responses using over 2,500 genetic signatures mapped to 1,100 genes.

4Endometriosis Test (TRANSCEND)
CategoryGenetic Diagnostic Test
Description

Non-invasive buccal swab test to evaluate patient risk of endometriosis and the biological mechanisms underpinning their disease. Enables rapid differential triage and identification of effective treatments for patients presenting with pelvic pain.

5ME/CFS Genetic Test
CategoryGenetic Diagnostic Test
Description

Genetic biomarker tests identifying over 250 core genes associated with myalgic encephalomyelitis, revealing disease subgroups and drug repurposing opportunities. Validated across DecodeME and UK Biobank cohorts.

6Long COVID Diagnostic Test
CategoryGenetic Diagnostic Test
Description

Biomarker-driven test to evaluate individual genetic risk of developing long COVID and distinguish it from other post-viral syndromes. Based on reproducible genetic associations confirmed across US and UK diverse populations.

7Clinical Decision Support
CategoryClinical Decision Support Software
Description

Healthcare solution enabling clinicians to make evidence-based treatment decisions using mechanism-based patient stratification and biomarker insights.

8Clinical Trial Enrichment Service
CategoryDrug Development Services
Description

Drug development service using patient stratification biomarkers to identify super-responder subgroups, design faster and smaller trials, and provide companion diagnostic biomarkers for regulatory approval.

9Drug Discovery Service
CategoryDrug Discovery Services
Description

Novel drug target discovery and drug repurposing identification using combinatorial analytics to find mechanistic links between disease biology and therapeutic opportunities.

10DiseaseBank
CategoryBiomedical Database
Description

Comprehensive database of disease mechanisms and genetic insights supporting research and clinical decision-making across 60+ chronic diseases.

Scale indicator19 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-25
Description

Strategic collaboration to develop GLP-1 pharmacogenomics tests for payors and healthcare systems. Phase 1 analyzed 4,600 patients identifying 2,500+ genetic signatures; Phase 2 expanding to 25,000 patients. Commercialization agreement signed April 2026 for LDT and consumer DNA tests launching H2 2026.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-08
Description

Research partnership for long COVID and ME/CFS studies. Successfully reproduced 88% of long COVID genetic associations across US and UK populations. Funded MELO clinical study with Metrodora Institute.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

2025 co-development agreement for immuno-oncology candidates using AI-driven analytics platforms from both companies.

4Metrodora Institute
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Clinical research collaboration for MetX and MELO studies evaluating biomarkers in ME/CFS and long COVID. Partnership for decentralized patient engagement, specimen collection, and genotyping to advance diagnostic tests and drug repurposing candidates.

precisionlife.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-12-01
Description

LOCOME project partnership leveraging DecodeME study data to categorize ME and Long COVID patients into distinct subgroups. £600,000+ Innovate UK funding. Collaboration to identify disease signatures and stratification tools for clinical trials.

6University of Edinburgh
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-12-01
Description

Academic research partnership with DecodeME team led by Prof Chris Ponting for ME/CFS genetic studies. LOCOME project collaboration analyzing DecodeME and UK Biobank datasets to identify disease mechanisms and patient subgroups.

precisionlife.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

2023 R&D partnership using PrecisionLife's combinatorial analytics platform for biomarker discovery and drug development. Strategic collaboration for identifying drug targets and patient stratification biomarkers.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight8 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-driven genomics and multimodal data analytics platform serving hospitals, labs, and biopharma for clinical genomics and patient stratification. Comparable to PrecisionLife's combinatorial analytics approach in chronic disease and biopharma R&D support.

2Tempus Labs
TypeBroad incumbent
Description

Large precision medicine company applying AI to multi-modal patient data including genomics, transcriptomics, and clinical records to support diagnostics, therapy selection, and biopharma drug development. Comparable in data modality breadth and biopharma service model.

TypeDirect peer
Description

AI precision medicine company with biopharma co-development model (including the existing PrecisionLife partnership). Uses multimodal patient data to identify targets, biomarkers, and patient subgroups for drug development, particularly in oncology.

TypeDirect peer
Description

Clinical genomics and rare disease diagnostics platform leveraging AI for variant interpretation and patient stratification. Comparable as a UK-based precision medicine company providing clinical decision support and biopharma genomics services.

TypeEmerging player
Description

Genomic data management and analytics platform enabling precision medicine and biopharma R&D across European and global markets. Comparable in B2B genomics infrastructure and partnership-based commercialization.

TypeEmerging player
Description

AI-driven clinical genomic interpretation platform for rare disease and hereditary conditions, serving clinical labs and hospitals. Comparable in applying AI to clinical genomic decision-making but more focused on rare disease than chronic complex disease.

TypeBroad incumbent
Description

Precision health company combining whole genome sequencing, advanced imaging, and AI-driven analytics for disease risk prediction and preventive care. Comparable in whole-genome-driven mechanism-based risk prediction.

TypeDirect peer
Description

AI-driven drug discovery company using multi-omic patient data to identify novel targets and patient subgroups for complex diseases including neurodegenerative conditions. Comparable in AI + multi-omics approach to mechanism-based drug discovery.

TypeDirect peer
Description

UK-based genomic analytics company using polygenic risk scores and population genomics for disease risk prediction and biopharma research. Comparable in UK origin, chronic disease focus, and B2B model serving payors and pharma.

TypeEmerging player
Description

Real-world multi-omic and clinical data platform partnered with the NHS to support biopharma drug development and precision medicine research. Comparable in multi-omic + clinical data integration for biopharma partnerships.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights1 record

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Precisionlife

Precision Medicine AI Softwareprecisionlife.com

Precisionlife firmographics

Firmographics
Name
Precisionlife
Legal name
PrecisionLife Ltd
Website
https://precisionlife.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Precisionlife industry classification

Industry
Product category
Precision Medicine AI Software
NAICS
Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAANAA
Genomic Profiling & Sequencing-Based Precision Medicine
SECONDARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAF
Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Precision medicine AI
  • Combinatorial analytics platform
  • Genetic diagnostic testing
  • Biomarker discovery services
  • Clinical trial enrichment

Where Precisionlife is headquartered

Location

Headquarters

HQ city
Witney
HQ country
United Kingdom
HQ region
Europe

Offices5 records

Markets served

Precisionlife business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Diagnostic Tests (Mechanostics®): Revenue from development and commercialization of genetic diagnostic tests including GLP-1 response tests, disease risk prediction tests, and patient stratification tools for healthcare providers and payors.
  2. Biopharmaceutical Partnerships: Revenue from partnerships with pharmaceutical companies for drug discovery, clinical trial enrichment, patient stratification biomarkers, and drug repurposing opportunities. Includes biomarker discovery services and companion diagnostic development.
  3. Payor-Facing Tests: Mechanism-based tests to help payors and healthcare systems determine where therapies are most clinically and economically justified, supporting value-based reimbursement frameworks.
  4. Laboratory Developed Tests (LDTs): Revenue from laboratory developed tests commercialized through CLIA-certified laboratory partners, including consumer DNA tests and clinical diagnostic tests.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels8 records

Precisionlife product offering

Product offering

Core offering

PrecisionLife develops a proprietary AI-driven combinatorial analytics platform that identifies the biological mechanisms driving complex chronic diseases and enables high-resolution patient stratification. The company commercializes the Mechanostics® product line of non-invasive genetic tests for disease risk prediction, treatment response prediction, and patient stratification, and provides biomarker discovery, drug target identification, and clinical trial enrichment services to biopharmaceutical companies, healthcare systems, and payors.

Product overview

PrecisionLife offers a unified precision medicine platform centered on its Mechanostics® product line and proprietary Combinatorial Analytics Platform. The core offering includes non-invasive genetic tests that identify disease mechanisms and predict treatment response across 60+ chronic diseases. Key products include GLP-1 response prediction tests (LDT and consumer DNA), endometriosis tests (TRANSCEND), ME/CFS genetic tests, and long COVID diagnostic tests. The company provides additional services including Clinical Decision Support, Drug Discovery, and Clinical Trial Enrichment using mechanism-based patient stratification. All products leverage the Combinatorial Analytics Platform to discover biomarkers invisible to traditional GWAS methods.

Differentiator

Problem solved

Functional benefit

Brands

  • Mechanostics®: A new generation of diagnostic and prognostic tools to accurately identify the cause of disease and personalize interventions, based on precision medicine AI technology.

Products and services

  • Mechanostics® First-in-class, non-invasive genetic tests that leverage PrecisionLife's proprietary AI-driven combinatorial analytics to identify the underlying biological mechanisms driving disease in patients. Enables disease risk prediction, mechanism identification, and precision treatment matching across 60+ chronic diseases.
  • Combinatorial Analytics Platform Proprietary AI platform that identifies combinations of genetic variants associated with disease risk and treatment response. Generates 10-100x more signal from data than traditional GWAS approaches, discovering disease mechanisms invisible to other analytical methods.
  • GLP-1 Response Prediction Tests DNA-based tests (both LDT and direct-to-consumer) that predict individual patient response, safety, and tolerability to GLP-1 receptor agonists. Identifies biomarkers for glycemic control (HbA1c) and weight loss (BMI) responses using over 2,500 genetic signatures mapped to 1,100 genes.
  • Endometriosis Test (TRANSCEND) Non-invasive buccal swab test to evaluate patient risk of endometriosis and the biological mechanisms underpinning their disease. Enables rapid differential triage and identification of effective treatments for patients presenting with pelvic pain.
  • ME/CFS Genetic Test Genetic biomarker tests identifying over 250 core genes associated with myalgic encephalomyelitis, revealing disease subgroups and drug repurposing opportunities. Validated across DecodeME and UK Biobank cohorts.
  • Long COVID Diagnostic Test Biomarker-driven test to evaluate individual genetic risk of developing long COVID and distinguish it from other post-viral syndromes. Based on reproducible genetic associations confirmed across US and UK diverse populations.
  • Clinical Decision Support Healthcare solution enabling clinicians to make evidence-based treatment decisions using mechanism-based patient stratification and biomarker insights.
  • Clinical Trial Enrichment Service Drug development service using patient stratification biomarkers to identify super-responder subgroups, design faster and smaller trials, and provide companion diagnostic biomarkers for regulatory approval.
  • Drug Discovery Service Novel drug target discovery and drug repurposing identification using combinatorial analytics to find mechanistic links between disease biology and therapeutic opportunities.
  • DiseaseBank Comprehensive database of disease mechanisms and genetic insights supporting research and clinical decision-making across 60+ chronic diseases.

Quantifiable outcome

  • Identified over 2,500 genetic signatures for GLP-1 efficacy in 100% of 4,600 patients studied
  • +4 more outcomes

Companies that use Precisionlife

Customer profile

Named customers10 records

Segments4 records

Ideal customer profiles4 records

Precisionlife technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature7 records

Precisionlife partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core.

  • Ovation.iocoreStrategic or Co-development Partner · 25 November 2025Strategic collaboration to develop GLP-1 pharmacogenomics tests for payors and healthcare systems. Phase 1 analyzed 4,600 patients identifying 2,500+ genetic signatures; Phase 2 expanding to 25,000 patients. Commercialization agreement signed April 2026 for LDT and consumer DNA tests launching H2 2026.
  • Complex Disorders AlliancecoreStrategic or Co-development Partner · 8 May 2025Research partnership for long COVID and ME/CFS studies. Successfully reproduced 88% of long COVID genetic associations across US and UK populations. Funded MELO clinical study with Metrodora Institute.
  • OwkincoreStrategic or Co-development Partner · 1 January 20252025 co-development agreement for immuno-oncology candidates using AI-driven analytics platforms from both companies.
  • Metrodora InstitutecoreStrategic or Co-development Partner · 1 January 2024Clinical research collaboration for MetX and MELO studies evaluating biomarkers in ME/CFS and long COVID. Partnership for decentralized patient engagement, specimen collection, and genotyping to advance diagnostic tests and drug repurposing candidates.
  • Action for MEcoreStrategic or Co-development Partner · 1 December 2023LOCOME project partnership leveraging DecodeME study data to categorize ME and Long COVID patients into distinct subgroups. £600,000+ Innovate UK funding. Collaboration to identify disease signatures and stratification tools for clinical trials.
  • University of EdinburghcoreStrategic or Co-development Partner · 1 December 2023Academic research partnership with DecodeME team led by Prof Chris Ponting for ME/CFS genetic studies. LOCOME project collaboration analyzing DecodeME and UK Biobank datasets to identify disease mechanisms and patient subgroups.
  • Absci CorpcoreStrategic or Co-development Partner · 1 January 20232023 R&D partnership using PrecisionLife's combinatorial analytics platform for biomarker discovery and drug development. Strategic collaboration for identifying drug targets and patient stratification biomarkers.

Scale indicators19 records

Recent moves8 records

Expansion highlights8 records

Precisionlife competitors and assessment

Company assessment

Direct peers

  • Sophia Genetics: AI-driven genomics and multimodal data analytics platform serving hospitals, labs, and biopharma for clinical genomics and patient stratification. Comparable to PrecisionLife's combinatorial analytics approach in chronic disease and biopharma R&D support.
  • Owkin: AI precision medicine company with biopharma co-development model (including the existing PrecisionLife partnership). Uses multimodal patient data to identify targets, biomarkers, and patient subgroups for drug development, particularly in oncology.
  • Congenica: Clinical genomics and rare disease diagnostics platform leveraging AI for variant interpretation and patient stratification. Comparable as a UK-based precision medicine company providing clinical decision support and biopharma genomics services.
  • Verge Genomics: AI-driven drug discovery company using multi-omic patient data to identify novel targets and patient subgroups for complex diseases including neurodegenerative conditions. Comparable in AI + multi-omics approach to mechanism-based drug discovery.
  • Genomics PLC: UK-based genomic analytics company using polygenic risk scores and population genomics for disease risk prediction and biopharma research. Comparable in UK origin, chronic disease focus, and B2B model serving payors and pharma.

Broad incumbents

  • Tempus Labs: Large precision medicine company applying AI to multi-modal patient data including genomics, transcriptomics, and clinical records to support diagnostics, therapy selection, and biopharma drug development. Comparable in data modality breadth and biopharma service model.
  • Human Longevity Inc: Precision health company combining whole genome sequencing, advanced imaging, and AI-driven analytics for disease risk prediction and preventive care. Comparable in whole-genome-driven mechanism-based risk prediction.

Emerging players

  • BC Platforms: Genomic data management and analytics platform enabling precision medicine and biopharma R&D across European and global markets. Comparable in B2B genomics infrastructure and partnership-based commercialization.
  • Fabric Genomics: AI-driven clinical genomic interpretation platform for rare disease and hereditary conditions, serving clinical labs and hospitals. Comparable in applying AI to clinical genomic decision-making but more focused on rare disease than chronic complex disease.
  • Arcturis Data: Real-world multi-omic and clinical data platform partnered with the NHS to support biopharma drug development and precision medicine research. Comparable in multi-omic + clinical data integration for biopharma partnerships.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights1 record

Customer concentration

Precisionlife social profiles

Digital presence

Precisionlife compliance and trust

Trust signal

Compliance2 records

Precisionlife financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Precisionlife leadership team

Management profile

Number of profiles

Profiles12 records

Precisionlife funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Precisionlife M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Precisionlife

What does Precisionlife do?

PrecisionLife develops a proprietary AI-driven combinatorial analytics platform that identifies the biological mechanisms driving complex chronic diseases and enables high-resolution patient stratification. The company commercializes the Mechanostics® product line of non-invasive genetic tests for disease risk prediction, treatment response prediction, and patient stratification, and provides biomarker discovery, drug target identification, and clinical trial enrichment services to biopharmaceutical companies, healthcare systems, and payors.

Is Precisionlife a public or private company?

Precisionlife is a private company. It is classified as venture growth investor backed and is currently operating.

When was Precisionlife founded?

Precisionlife was founded in 2015. It employs 11 to 50 people.

Where is Precisionlife based?

Precisionlife is headquartered in Witney, United Kingdom, in the Europe region.

How does Precisionlife make money?

Four revenue lines are on record. Diagnostic Tests (Mechanostics®) is the primary driver. The others are biopharmaceutical Partnerships, payor-Facing Tests and laboratory Developed Tests (LDTs).

Who are Precisionlife's main competitors?

Direct peers on record are Sophia Genetics, Owkin, Congenica, Verge Genomics and Genomics PLC. Broad incumbents are Tempus Labs and Human Longevity Inc. Emerging players are BC Platforms, Fabric Genomics and Arcturis Data.

Does Precisionlife have an API?

No public API is recorded for Precisionlife.

What industry is Precisionlife in?

Precisionlife's product category is Precision Medicine AI Software. Its primary akta.pro industry code is HLAAANAA, Genomic Profiling & Sequencing-Based Precision Medicine, with a secondary code of HLAAANAF, Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics). Its NAICS code is 6215 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswirePrecisionLife's Post COVID DNA Wellness Report Places World-Leading Long COVID Genetic Research Directly in Consumers' HandsPrecisionLife launched the Post COVID DNA Wellness Report, offering consumers a cheek swab kit to analyze their DNA against long COVID research patterns. The report covers six biological mechanisms and over 180 genes linked to long COVID, with 5.3% of U.S. adults affected. It is intended for wellness and educational purposes only, not for diagnosis or treatment.PR NewswirePrecisionLife Selects Gencove as US Partner to Launch and Deliver DNA Wellness ReportsPrecisionLife selected Gencove as its US partner to launch DNA wellness reports, combining Gencove's low-pass whole genome sequencing with PrecisionLife's AI analysis. The first product, the Post COVID DNA Wellness Report, compares genomes to long COVID research patterns for educational purposes only. Further reports are planned over the next 12 months.BioSpacePrecisionLife strengthens leadership team with appointments of Dr Pradip Banerjee and Dr Kam PooniPrecisionLife appointed Dr Pradip Banerjee as Independent Non-Executive Director and Dr Kam Pooni as Chief Product Officer. Dr Banerjee joins after the Series A round, bringing over 30 years of life sciences and healthcare experience. Dr Pooni will lead the Mechanostics portfolio, advancing the company's transition to a commercial-stage organization.The Motley FoolThe 1 AI Stock I'd Put in a Time Capsule and Open in 2036The author recommends Absci Corp (ABSI) as a long-term AI drug discovery investment to hold until 2036, describing it as a generative AI company that designs protein-based drugs computationally before lab testing. The company's platform has attracted partnerships with major entities including a 2022 research collaboration with Merck, a 2023 R&D partnership with PrecisionLife, and a 2025 co-development agreement with Owkin for immuno-oncology candidates. While the author acknowledges significant risks including drug development failures, regulatory hurdles, and potential share dilution, they argue the platform approach could generate multiple drugs over a decade unlike single-asset biotech companies.InsideprecisionmedicineDNA Tests to Predict GLP-1 Drug Response to Launch in 2026PrecisionLife and Ovation.io have signed a commercialization agreement to launch GLP-1 response genetic tests by 2026, available as both direct-to-consumer and laboratory-developed tests. The companies identified combinatorial biomarker signatures that can quantitatively predict which patients will respond to GLP-1 therapies like semaglutide and tirzepatide, and sustain that response over time. The tests aim to help patients, providers, and payors make more informed decisions about GLP-1 drug selection and coverage, while also offering drug developers tools for patient stratification in clinical trials.PR NewswirePrecisionLife and Ovation ink collaboration agreement to launch GLP-1 stratification LDT and consumer GLP-1 DNA test in H2 2026Ovation.io and PrecisionLife announced a collaboration agreement to commercialize outputs from PrecisionLife's analysis of Ovation's GLP-1 receptor agonist dataset, with plans to launch a consumer DNA test and laboratory developed test in H2 2026. The companies have identified distinct quantitative markers for glycemic control that are different from those for weight loss, along with novel biological mechanisms associated with treatment response. The partners aim to enable more precise matching of patients to GLP-1 therapies and reduce unnecessary treatment costs by identifying which patients are most likely to respond.PR NewswirePrecisionLife and Ovation identify first potential genetic biomarkers to quantitatively predict GLP-1 efficacy responsePrecisionLife and Ovation.io completed Phase 1 of their collaboration to develop genetic biomarkers predicting patient response to GLP-1 receptor agonist therapies, identifying over 2,500 genetic signatures mapped to 1,100 genes with 15 main genetic mechanisms driving drug efficacy. The biomarkers were identified in 100% of the 4,600 patients studied, with findings applicable to approximately 50% of patients who typically discontinue GLP-1 treatment within 12 months. The companies are now expanding into Phase 2, scaling the dataset to up to 25,000 patients to validate efficacy signals and identify safety and tolerability markers, with potential to inform payor reimbursement policies.PR NewswirePrecisionLife and Ovation Partner to Develop Precision Medicine Test to Inform Reimbursement of GLP-1 Anti-Obesity DrugsPrecisionLife and Ovation.io announced a collaboration to develop biomarkers for GLP-1 therapies to support value-based reimbursement policies and improve patient outcomes. The initiative leverages Ovation's multiomic data and PrecisionLife's AI analytics to identify responders and predict drug safety, efficacy, and tolerability.openPR.comPrecision Diagnostics Market Future Business Opportunities 2025-2032 | SomaLogic, Ezra, Egnite, PrecisionLifeThe global precision diagnostics market is forecast to grow from USD 95.54 billion in 2025 to USD 224.90 billion by 2032, a CAGR of 13%. North America leads adoption, with oncology as the largest application segment. Key players include SomaLogic, Ezra, Egnite, and PrecisionLife.